Role of angiotensin converting enzyme inhibitor [captopril] in proteinuria, glomerular filtration rate and lipid profile in NIDDM patients

Clinical trial has shown the beneficial effects of captopril in delaying the progression of diabetic renal disease. We performed an analysis to determine in efficacy of captopril in slowing the progression of renal disease over a broad range of functional renal and extra renal impairment. Treatment of individuals with microscopic and macroscopic proteinuria in NIDDM patients with preexisting hypertension and hyperlipidemia by captopril delays, inhibit or even revert the disease